Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HY-028
- Development stage
- Unknown
- Lead developer
- Juventas Cell Therapy
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
HY-028 is an intravenous (IV) formulation of dofetilide, a Class III antiarrhythmic agent, being developed by Hyloris Pharmaceuticals. Dofetilide is traditionally administered as an oral capsule (marketed as Tikosyn) for the conversion and maintenance of normal sinus rhythm in patients with atrial fibrillation or atrial flutter. The oral initiation of dofetilide is strictly regulated, requiring a minimum three-day hospital stay for continuous ECG monitoring due to the risk of induced arrhythmia (Torsades de Pointes) during the titration phase. HY-028 is designed as a "Value Added Medicine" to provide a faster onset of action and more precise control over plasma concentrations in a hospital setting, potentially simplifying the treatment initiation process and improving patient management for acute cardioversion.
- Other names
- Dofetilide IVIntravenous dofetilide
02
Targets
KCNH2 (Voltage-gated potassium channel subfamily H member 2)
Beyond the preview
Go deeper on HY-028.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HY-028.